Optogenetic Neuromodulation via Genetically Targeted Opsins
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for neuromodulation in clinical settings lack specificity and temporal control, as pharmacological and electrical techniques are either non-specific or have significant clinical downsides, while optogenetic technologies, which use light-sensitive proteins, offer promise but require effective delivery and illumination systems for medical applications.
Innovation Solution
A system comprising implantable optical applicators and a controller to deliver light to targeted nerves, utilizing genetically modified opsin proteins and various light sources to create directed action potentials, allowing for precise excitation or inhibition of neural activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If pharmacological techniques are used for neuromodulation, then cell type specificity is improved, but response time is too slow (minutes vs. milliseconds)
Solution Approach 1:
The patent replaces pharmacological chemical mechanisms with optical mechanisms. Light-sensitive proteins (opsins) expressed in specific neuron types enable direct optical control of neural activity, achieving millisecond response times while maintaining cell type specificity through genetic targeting. This substitution of chemical action with optical action resolves the speed limitation of pharmacological approaches.
Solution Approach 2:
The patent changes the fundamental interaction parameter from chemical concentration (pharmacological) to light intensity and wavelength (optical). By using light of specific wavelengths to activate opsins, the system achieves rapid temporal control (millisecond scale) while maintaining specificity through wavelength selection and genetic expression patterns, thus resolving the time-scale contradiction.
2Speed
If electrical stimulation techniques are used for neuromodulation, then response time is improved (millisecond scale), but cell type specificity is reduced
Solution Approach 1:
The patent replaces electrical stimulation with optical stimulation. By using light-sensitive proteins that can be selectively activated by wavelength-specific light, the system achieves both rapid response (millisecond scale) and cell type specificity. The optical mechanism allows spatial and spectral selectivity that electrical stimulation cannot provide, resolving the specificity limitation.
Solution Approach 2:
The patent applies local quality by using wavelength-specific light activation combined with spatially targeted illumination. Different neuron types expressing different opsins can be selectively activated by choosing appropriate wavelengths and illumination locations, achieving cell type specificity while maintaining fast response times. This localized selective activation is impossible with non-specific electrical stimulation.
3Measurement precision
If optogenetic technologies are implemented, then both cell type specificity and response time are improved, but device complexity increases due to requirement for gene delivery and illumination systems
Solution Approach 1:
The patent segments the optogenetic system into distinct functional components: (1) genetic delivery system (viral vectors or other delivery mechanisms), (2) light-sensitive protein expression in target cells, (3) illumination system (light sources and delivery optics), and (4) control system. This segmentation allows each component to be optimized independently and facilitates clinical translation by addressing complexity in modular fashion.
Solution Approach 2:
The patent uses light-sensitive proteins (opsins) as an intermediary between the illumination system and the neural tissue. These proteins serve as a biological mediator that converts optical energy into electrical signals, enabling precise control of neural activity. The opsin acts as a transducer that simplifies the overall system by providing a direct optical-to-electrical conversion mechanism within the tissue.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enables precise and specific neuromodulation with low latency and high specificity, addressing clinical challenges such as pain management and hypertension by controlling neural activity with optogenetic technologies.
Implementation Method 1
light-sensitive proteins, such as the so-called 'opsins'. These light-sensitive transmembrane proteins may be covalently bonded to chromophore retinal, which upon absorption of light, isomerizes to activate the protein
Implementation Method 2
which upon absorption of light, isomerizes to activate the protein
Implementation Method 3
A system comprising implantable optical applicators and a controller to deliver light to targeted nerves
Data Source
AI summary
Configurations are described for utilizing light-activated proteins within cell membranes and subcellular regions to assist with medical treatment paradigms, such as hypertension treatment via anatomically specific and temporally precise modulation of renal plexus activity. The invention provides for proteins, nucleic acids, vectors and methods for genetically targeted expression of light-sensitive proteins to specific cells or defined cell populations. In particular the invention provides systems, devices, and methods for millisecond-timescale temporal control of certain cell activities using moderate light intensities, such as the generation or inhibition of electrical spikes in nerve cells and other excitable cells.